Anti-VEGF Drugs for Angiogenesis-related Disease Market Report – Research, Industry Analysis Reports and Market Demands

Global Anti-VEGF Drugs for Angiogenesis-related Disease Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Ranibizumab
- 1.3.3 Brolucizumab
- 1.3.4 Aflibercept
- 1.3.5 Conbercept
- 1.3.6 Faricimab
- 1.3.7 Others
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Tumor
- 1.4.3 Eye Diseases
- 1.4.4 Others
1.5 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size & Forecast
- 1.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (2021-2032)
- 1.5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer

3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Manufacturer (2021-2026)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Manufacturer (2021-2026)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2025
- 3.4.3 Top 6 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2025
3.5 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Overall Company Footprint Analysis
- 3.5.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Region Footprint
- 3.5.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
- 3.5.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
- 4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2021-2032)
- 4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2021-2032)
- 4.1.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2021-2032)
4.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021-2032)
4.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021-2032)
4.4 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021-2032)
4.5 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021-2032)
4.6 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2021-2032)
5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
6.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2021-2032)
6.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2021-2032)

7 North America

7.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
7.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
7.3 North America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
- 7.3.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2021-2032)
- 7.3.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
8.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
8.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
- 8.3.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
- 9.3.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
10.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
10.3 South America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
- 10.3.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2021-2032)
- 10.3.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
- 11.3.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
12.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
12.3 Anti-VEGF Drugs for Angiogenesis-related Disease Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Anti-VEGF Drugs for Angiogenesis-related Disease and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Drugs for Angiogenesis-related Disease
13.3 Anti-VEGF Drugs for Angiogenesis-related Disease Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
14.3 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Anti-VEGF Drugs for Angiogenesis-related Disease market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
This report is a detailed and comprehensive analysis for global Anti-VEGF Drugs for Angiogenesis-related Disease market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anti-VEGF Drugs for Angiogenesis-related Disease market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-VEGF Drugs for Angiogenesis-related Disease market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-VEGF Drugs for Angiogenesis-related Disease market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-VEGF Drugs for Angiogenesis-related Disease market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-VEGF Drugs for Angiogenesis-related Disease
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-VEGF Drugs for Angiogenesis-related Disease market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics, Anke Biotechnology, Shenzhen Kangzhe Pharmaceutical Co Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Anti-VEGF Drugs for Angiogenesis-related Disease market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Ranibizumab
Brolucizumab
Aflibercept
Conbercept
Faricimab
Others
Market segment by Application
Tumor
Eye Diseases
Others
Major players covered
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Rongchang Biology
Youzhiyou Bio
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anti-VEGF Drugs for Angiogenesis-related Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, with price, sales quantity, revenue, and global market share of Anti-VEGF Drugs for Angiogenesis-related Disease from 2021 to 2026.
Chapter 3, the Anti-VEGF Drugs for Angiogenesis-related Disease competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-VEGF Drugs for Angiogenesis-related Disease breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anti-VEGF Drugs for Angiogenesis-related Disease market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drugs for Angiogenesis-related Disease.
Chapter 14 and 15, to describe Anti-VEGF Drugs for Angiogenesis-related Disease sales channel, distributors, customers, research findings and conclusion.

Buy now